First phase of Akeso's production base begins operation

The first phase of Akeso's biopharmaceutical production base at China-Singapore Guangzhou Knowledge City in Guangzhou's Huangpu district began operation on March 10 with a capacity of 20,000 liters.

Akeso is a domestically leading enterprise in the independent R&D of monoclonal antibody drugs. It is advancing more than 40 clinical projects in China, the United States, Australia and New Zealand with one to two new drugs expected to be approved for marketization every year.

The first phase of Akeso's biopharmaceutical production base at China-Singapore Guangzhou Knowledge City begins operation on March 10.

With an investment of more than 2 billion yuan ($307.3 million), the biopharmaceutical production base adopts world leading design concepts and equipment. Once operational, it will boast a total capacity of 40,000 liters and will be among the largest of its kind in the Guangdong-Hong Kong-Macao Greater Bay Area.

The project will support Akeso's vision of providing affordable innovative antibody drug solutions to global patients and constantly creating societal and business values.

Share - WeChat